Research programme: bisphosphocins - Lakewood-Amedex

Drug Profile

Research programme: bisphosphocins - Lakewood-Amedex

Alternative Names: Bisphosphocins; Nu 2; Nu 4; Nu 5; Nu 8; NuBiotics - Lakewood-Amedex; Nubiotics research programme - Oligos Etc.

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oligos Etc.
  • Developer Lakewood Amedex
  • Class Antibacterials; Nucleotides
  • Mechanism of Action Cell membrane structure modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Infections; Urinary tract infections

Most Recent Events

  • 04 Apr 2017 Lakewood-Amedex plans to file an IND application for NU 8 for Urinary tract infections
  • 04 Apr 2017 Antimicrobial data from preclinical studies in Infections released by Lakewood-Amedex
  • 23 Jan 2017 Preclinical trials in Urinary tract infections in USA (IV) before January 207 (Lakewood Amedex pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top